Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients

Li Rong Yu, Zhijun Cao, Issam Makhoul, Jaclyn R. Daniels, Vicki Klimberg, Jeanne Y. Wei, Jane P.F. Bai, Jinong Li, Julia T. Lathrop, Richard D. Beger, Valentina K. Todorova

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential cardiovascular biomarkers for the prediction of DOX-induced cardiotoxicity. Plasma samples were collected before (T0), and after the first (T1) and the second (T2) cycles of DOX-based chemotherapy of 27 breast cancer patients, including five patients who presented with >10% decline of left ventricular ejection fraction (LVEF), five patients with LVEF decline of 5–10%, and 17 patients who maintained normal LVEF at the end of chemotherapy (240 mg/m2 cumulative dose of DOX from four cycles of treatment). Multiplex immunoassays were used to screen plasma samples for 40 distinct chemokines, nine matrix metalloproteinases, 33 potential markers of cardiovascular diseases, and the fourth-generation cardiac troponin T assay. The results showed that the patients with abnormal decline of LVEF (>10%) had lower levels of CXCL6 and sICAM-1 and higher levels of CCL23 and CCL27 at T0; higher levels of CCL23 and lower levels of CXCL5, CCL26, CXCL6, GM-CSF, CXCL1, IFN-γ, IL-2, IL-8, CXCL11, CXCL9, CCL17, and CCL25 at T1; and higher levels of MIF and CCL23 at T2 than the patients who maintained normal LVEF. Patients with LVEF decline of 5–10% had lower plasma levels of CXCL1, CCL3, GDF-15, and haptoglobin at T0; lower levels of IL-16, FABP3, and myoglobin at T1; and lower levels of myoglobin and CCL23 at T2 as compared to the patients who maintained normal LVEF. This pilot study identified potential biomarkers that may help predict which patients are vulnerable to DOX-induced cardiotoxicity although further validation is needed in a larger cohort of patients. Impact statement: Drug-induced cardiotoxicity is one of the major concerns in drug development and clinical practice. It is critical to detect potential cardiotoxicity early before onset of symptomatic cardiac dysfunction or heart failure. Currently there are no qualified clinical biomarkers for the prediction of cardiotoxicity caused by cancer treatment such as doxorubicin (DOX). By using multiplex immunoassays, we identified proteins with significantly changed plasma levels in a group of breast cancer patients who were treated with DOX-based chemotherapy and produced cardiotoxicity. These proteins were associated with immune response and were identified before DOX treatment or at early doses of treatment, thus they could be potential predictive biomarkers of cardiotoxicity although further validation is required to warrant their clinical values.

Original languageEnglish (US)
Pages (from-to)248-255
Number of pages8
JournalExperimental Biology and Medicine
Volume243
Issue number3
DOIs
StatePublished - Feb 1 2018
Externally publishedYes

Fingerprint

Biomarkers
Doxorubicin
Breast Neoplasms
Chemotherapy
Stroke Volume
Plasmas
Proteins
Oncology
Myoglobin
Chemokines
Drug Therapy
Growth Differentiation Factor 15
Interleukin-16
Immunoassay
Troponin T
Haptoglobins
Cardiotoxicity
Granulocyte-Macrophage Colony-Stimulating Factor
Heart Failure
Matrix Metalloproteinases

Keywords

  • breast cancer
  • Cardiotoxicity
  • chemokines
  • doxorubicin
  • multiplex immunoassays
  • predictive biomarkers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients. / Yu, Li Rong; Cao, Zhijun; Makhoul, Issam; Daniels, Jaclyn R.; Klimberg, Vicki; Wei, Jeanne Y.; Bai, Jane P.F.; Li, Jinong; Lathrop, Julia T.; Beger, Richard D.; Todorova, Valentina K.

In: Experimental Biology and Medicine, Vol. 243, No. 3, 01.02.2018, p. 248-255.

Research output: Contribution to journalArticle

Yu, LR, Cao, Z, Makhoul, I, Daniels, JR, Klimberg, V, Wei, JY, Bai, JPF, Li, J, Lathrop, JT, Beger, RD & Todorova, VK 2018, 'Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients', Experimental Biology and Medicine, vol. 243, no. 3, pp. 248-255. https://doi.org/10.1177/1535370217746383
Yu, Li Rong ; Cao, Zhijun ; Makhoul, Issam ; Daniels, Jaclyn R. ; Klimberg, Vicki ; Wei, Jeanne Y. ; Bai, Jane P.F. ; Li, Jinong ; Lathrop, Julia T. ; Beger, Richard D. ; Todorova, Valentina K. / Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients. In: Experimental Biology and Medicine. 2018 ; Vol. 243, No. 3. pp. 248-255.
@article{67b8d1b4361b4dcd91db33ce2e996be7,
title = "Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients",
abstract = "Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential cardiovascular biomarkers for the prediction of DOX-induced cardiotoxicity. Plasma samples were collected before (T0), and after the first (T1) and the second (T2) cycles of DOX-based chemotherapy of 27 breast cancer patients, including five patients who presented with >10{\%} decline of left ventricular ejection fraction (LVEF), five patients with LVEF decline of 5–10{\%}, and 17 patients who maintained normal LVEF at the end of chemotherapy (240 mg/m2 cumulative dose of DOX from four cycles of treatment). Multiplex immunoassays were used to screen plasma samples for 40 distinct chemokines, nine matrix metalloproteinases, 33 potential markers of cardiovascular diseases, and the fourth-generation cardiac troponin T assay. The results showed that the patients with abnormal decline of LVEF (>10{\%}) had lower levels of CXCL6 and sICAM-1 and higher levels of CCL23 and CCL27 at T0; higher levels of CCL23 and lower levels of CXCL5, CCL26, CXCL6, GM-CSF, CXCL1, IFN-γ, IL-2, IL-8, CXCL11, CXCL9, CCL17, and CCL25 at T1; and higher levels of MIF and CCL23 at T2 than the patients who maintained normal LVEF. Patients with LVEF decline of 5–10{\%} had lower plasma levels of CXCL1, CCL3, GDF-15, and haptoglobin at T0; lower levels of IL-16, FABP3, and myoglobin at T1; and lower levels of myoglobin and CCL23 at T2 as compared to the patients who maintained normal LVEF. This pilot study identified potential biomarkers that may help predict which patients are vulnerable to DOX-induced cardiotoxicity although further validation is needed in a larger cohort of patients. Impact statement: Drug-induced cardiotoxicity is one of the major concerns in drug development and clinical practice. It is critical to detect potential cardiotoxicity early before onset of symptomatic cardiac dysfunction or heart failure. Currently there are no qualified clinical biomarkers for the prediction of cardiotoxicity caused by cancer treatment such as doxorubicin (DOX). By using multiplex immunoassays, we identified proteins with significantly changed plasma levels in a group of breast cancer patients who were treated with DOX-based chemotherapy and produced cardiotoxicity. These proteins were associated with immune response and were identified before DOX treatment or at early doses of treatment, thus they could be potential predictive biomarkers of cardiotoxicity although further validation is required to warrant their clinical values.",
keywords = "breast cancer, Cardiotoxicity, chemokines, doxorubicin, multiplex immunoassays, predictive biomarkers",
author = "Yu, {Li Rong} and Zhijun Cao and Issam Makhoul and Daniels, {Jaclyn R.} and Vicki Klimberg and Wei, {Jeanne Y.} and Bai, {Jane P.F.} and Jinong Li and Lathrop, {Julia T.} and Beger, {Richard D.} and Todorova, {Valentina K.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1177/1535370217746383",
language = "English (US)",
volume = "243",
pages = "248--255",
journal = "Experimental Biology and Medicine",
issn = "1535-3702",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients

AU - Yu, Li Rong

AU - Cao, Zhijun

AU - Makhoul, Issam

AU - Daniels, Jaclyn R.

AU - Klimberg, Vicki

AU - Wei, Jeanne Y.

AU - Bai, Jane P.F.

AU - Li, Jinong

AU - Lathrop, Julia T.

AU - Beger, Richard D.

AU - Todorova, Valentina K.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential cardiovascular biomarkers for the prediction of DOX-induced cardiotoxicity. Plasma samples were collected before (T0), and after the first (T1) and the second (T2) cycles of DOX-based chemotherapy of 27 breast cancer patients, including five patients who presented with >10% decline of left ventricular ejection fraction (LVEF), five patients with LVEF decline of 5–10%, and 17 patients who maintained normal LVEF at the end of chemotherapy (240 mg/m2 cumulative dose of DOX from four cycles of treatment). Multiplex immunoassays were used to screen plasma samples for 40 distinct chemokines, nine matrix metalloproteinases, 33 potential markers of cardiovascular diseases, and the fourth-generation cardiac troponin T assay. The results showed that the patients with abnormal decline of LVEF (>10%) had lower levels of CXCL6 and sICAM-1 and higher levels of CCL23 and CCL27 at T0; higher levels of CCL23 and lower levels of CXCL5, CCL26, CXCL6, GM-CSF, CXCL1, IFN-γ, IL-2, IL-8, CXCL11, CXCL9, CCL17, and CCL25 at T1; and higher levels of MIF and CCL23 at T2 than the patients who maintained normal LVEF. Patients with LVEF decline of 5–10% had lower plasma levels of CXCL1, CCL3, GDF-15, and haptoglobin at T0; lower levels of IL-16, FABP3, and myoglobin at T1; and lower levels of myoglobin and CCL23 at T2 as compared to the patients who maintained normal LVEF. This pilot study identified potential biomarkers that may help predict which patients are vulnerable to DOX-induced cardiotoxicity although further validation is needed in a larger cohort of patients. Impact statement: Drug-induced cardiotoxicity is one of the major concerns in drug development and clinical practice. It is critical to detect potential cardiotoxicity early before onset of symptomatic cardiac dysfunction or heart failure. Currently there are no qualified clinical biomarkers for the prediction of cardiotoxicity caused by cancer treatment such as doxorubicin (DOX). By using multiplex immunoassays, we identified proteins with significantly changed plasma levels in a group of breast cancer patients who were treated with DOX-based chemotherapy and produced cardiotoxicity. These proteins were associated with immune response and were identified before DOX treatment or at early doses of treatment, thus they could be potential predictive biomarkers of cardiotoxicity although further validation is required to warrant their clinical values.

AB - Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential cardiovascular biomarkers for the prediction of DOX-induced cardiotoxicity. Plasma samples were collected before (T0), and after the first (T1) and the second (T2) cycles of DOX-based chemotherapy of 27 breast cancer patients, including five patients who presented with >10% decline of left ventricular ejection fraction (LVEF), five patients with LVEF decline of 5–10%, and 17 patients who maintained normal LVEF at the end of chemotherapy (240 mg/m2 cumulative dose of DOX from four cycles of treatment). Multiplex immunoassays were used to screen plasma samples for 40 distinct chemokines, nine matrix metalloproteinases, 33 potential markers of cardiovascular diseases, and the fourth-generation cardiac troponin T assay. The results showed that the patients with abnormal decline of LVEF (>10%) had lower levels of CXCL6 and sICAM-1 and higher levels of CCL23 and CCL27 at T0; higher levels of CCL23 and lower levels of CXCL5, CCL26, CXCL6, GM-CSF, CXCL1, IFN-γ, IL-2, IL-8, CXCL11, CXCL9, CCL17, and CCL25 at T1; and higher levels of MIF and CCL23 at T2 than the patients who maintained normal LVEF. Patients with LVEF decline of 5–10% had lower plasma levels of CXCL1, CCL3, GDF-15, and haptoglobin at T0; lower levels of IL-16, FABP3, and myoglobin at T1; and lower levels of myoglobin and CCL23 at T2 as compared to the patients who maintained normal LVEF. This pilot study identified potential biomarkers that may help predict which patients are vulnerable to DOX-induced cardiotoxicity although further validation is needed in a larger cohort of patients. Impact statement: Drug-induced cardiotoxicity is one of the major concerns in drug development and clinical practice. It is critical to detect potential cardiotoxicity early before onset of symptomatic cardiac dysfunction or heart failure. Currently there are no qualified clinical biomarkers for the prediction of cardiotoxicity caused by cancer treatment such as doxorubicin (DOX). By using multiplex immunoassays, we identified proteins with significantly changed plasma levels in a group of breast cancer patients who were treated with DOX-based chemotherapy and produced cardiotoxicity. These proteins were associated with immune response and were identified before DOX treatment or at early doses of treatment, thus they could be potential predictive biomarkers of cardiotoxicity although further validation is required to warrant their clinical values.

KW - breast cancer

KW - Cardiotoxicity

KW - chemokines

KW - doxorubicin

KW - multiplex immunoassays

KW - predictive biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85041711747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041711747&partnerID=8YFLogxK

U2 - 10.1177/1535370217746383

DO - 10.1177/1535370217746383

M3 - Article

VL - 243

SP - 248

EP - 255

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 1535-3702

IS - 3

ER -